Trial reportEuropean radiology2017
Diffusion-weighted MR enterography for evaluating Crohn's disease: Effect of anti-peristaltic agent on the diagnosis of bowel inflammation.
Trial report in European radiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Pooled it
- Hyoscine butylbromide significantly decreases motion artefacts and allows better delineation of anatomic structures in mp-MRI of the prostate.European radiology · 2018Trial
- Motion Mitigation Techniques for Abdominal and Cardiac MR Imaging.Journal of magnetic resonance imaging : JMRI · 2026Review
- PET/MRI in paediatric inflammatory bowel disease - a prospective accuracy study.Clinical physiology and functional imaging · 2025Article
- Impact of deep learning-based reconstruction and anti-peristaltic agent on the image quality and diagnostic performance of magnetic resonance enterography comparing single breath-hold single-shot fast spin echo with and without anti-peristaltic agent.Quantitative imaging in medicine and surgery · 2024Article
- Technical Feasibility of Quantitative Measurement of Various Degrees of Small Bowel Motility Using Cine Magnetic Resonance Imaging.Korean journal of radiology · 2023Article
- Diffusion-weighted imaging in Crohn's disease.Radiologie (Heidelberg, Germany) · 2023Review
- [Magnetic resonance enterography/enteroclysis : Technical aspects and indications].Radiologie (Heidelberg, Germany) · 2023Review
- Role of abbreviated non-contrast-enhanced MR-enterography in the evaluation of Crohn's disease activity and complications as an alternative for full protocol contrast-enhanced study: A systematic review and meta-analysis.Research in diagnostic and interventional imaging · 2023Article
- Challenges and Strategies to Optimising the Quality of Small Bowel Magnetic Resonance Imaging in Crohn's Disease.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Ability of DWI to characterize bowel fibrosis depends on the degree of bowel inflammation.European radiology · 2019Article
- Can diffusion weighting replace gadolinium enhancement in magnetic resonance enterography for inflammatory bowel disease in children?Pediatric radiology · 2018Article
- Assessment of patency capsule retention using MR diffusion-weighted imaging.European radiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo prospectively investigate how Buscopan affects the diagnosis of bowel inflammation by diffusion-weighted imaging MR enterography (DWI-MRE) in Crohn's disease (CD).
methodsThirty CD patients without previous bowel surgery underwent DWI-MRE (b = 900 sec/mm
resultsWe analyzed 262 bowel segments. DWI-MRE without Buscopan significantly decreased sensitivity for both readers (58.8 % vs. 72.9 %, P = 0.046; 57.6 % vs. 85.9 %, P = 0.001) and did not significantly increase specificity (P = 0.085 and 0.396). Two readers noted that 28.6 % and 23.3 % of 262 bowel segments had greater diffusion restriction extent on DWI-MRE with Buscopan compared with DWI-MRE without Buscopan (P < 0.001) and 68.7 % and 74 %, respectively, had similar extent between them.
conclusionOmitting Buscopan caused a greater loss in sensitivity of DWI-MRE than false-positive reduction for diagnosing bowel inflammation in CD. KEY POINTS: • Omitting Buscopan significantly decreases DWI-MRE sensitivity for diagnosing bowel inflammation in CD. • Increase in the corresponding DWI-MRE specificity by omitting Buscopan is less apparent. • DWI-MRE without Buscopan underestimates the extent of bowel inflammation in CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.